Vertex (VRTX) to lead CRISPR Therapeutics for manufacture and commercialization of gene-editing therapy CTX001 which is being developed for treating SCD and TDT.
Jefferies analyst Maury Raycroft raised his rating on the stock to Buy from Hold and lifted his target for the share price to $172 from $165.
The relationship between Vertex Pharmaceuticals (NASDAQ: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP) is taking another big step forward. On Tuesday morning, the collaboration partners amended their agreement regarding CTX001 in a way that places more risk on Vertex's shoulders. CRISPR Therapeutics and Vertex had already agreed to co-commercialize and co-develop CTX001, an experimental gene therapy for patients with sickle cell disease (SCD) or transfusion-dependent beta-thalassemia (TDT).